Management
|
|
Anna Ljung, CEO , M.Sc. Econ.
Born 1980. Active in the company since 2006. Anna Ljung has more than 15 years of experience in the pharmaceutical industry, including as CFO of other biotech companies such as Athera Biotechnologies AB and Lipopetide AB and as independent technology licensing consultant. In addition to serving as CEO of Moberg Pharma, she also currently serves as Board member of Saniona AB and Chairman of the Board of OncoZenge AB.
Shareholding:30 311 shares, 240 000 performance share units and 30 000 employee stock options (30 000 shares may be subscribed to, based on the employee stock options).
|
 |
Annica Magnusson, Senior Director of Regulatory Affairs Born in 1963. Has worked for the company since 2013. Annica Magnusson is a pharmacist with more than 20 years of experience in international work within the pharmaceutical industry and Regulatory Affairs at AstraZeneca. Annica Mangusson has worked with the development and registration of pharmaceuticals, vaccines and medical devices in the EU, USA, Japan with several markets. Shareholding: 8 731 shares and 240 000 performance share units and 4273 employee stock options (4273 shares may be subscribed based on employee stock options).
|
 |
Mark Beveridge, Vice President Finance Born 1978. B. Com, GradDipCA. Active in the company since 2015. Mark Beveridge has more than 15 years of experience as an advisor in accounting, insurance and auditing, primarily from Crowe Horwath and Visma Services. Mark has also worked as an independent consultant within financial control, transaction consultancy and implementation of business systems. Shareholding: 57 416 shares and 240 000 performance share units and 4 273 employee stock options (4 273 shares may be subscribed based on employee stock options).
|
 |
Cindy Wong, Chief Medical Officer Born 1959. Dr Cindy Wong takes up the position at Moberg Pharma in late 2020. She brings extensive international experience in clinical development and registration of new products in a number of treatment areas including Dermatology. She has held positions as Vice President and Head of Global Clinical Development at Merz Pharmaceuticals and CMO at Q-Med/Galderma, as well as senior positions at regulatory authorities in both Sweden and Australia. Dr Wong is board certified in internal medicine and clinical immunology. She is a medical graduate from the University of Adelaide and has completed postgraduate training in Internal Medicine, Clinical Immunology and Immunopathology. Shareholding: 10 000 shares, 200 000 performance share units och 0 employee stock option. |
 |
Agneta Larhed, Vice President Pharmaceutical Innovation & Development Born 1964. Dr. Larhed has a broad experience of development, regulatory and quality within the pharmaceutical industry. She has held leading positions within the pharmaceutical industry and at regulatory authorities, including the Swedish MPA, Orexo and Q-Med. Dr Larhed is a pharmacist and obtained her PhD in Pharmaceutics from Uppsala university. She is also an expert in the European Pharmacopoeia expert group nr 12 Dosage forms and pharmaceutical technical procedures. Shareholding: 0 shares, 0 performance share units och 0 employee stock option. |
Current shareholding is not automatically updated for the moment. Insiders no longer have obligation to report there shareholding. According to the regulatory requirements, the data shall be updated once a year.